Skip to main content
Premium Trial:

Request an Annual Quote

DNA Electronics Licenses NAT Technology to geneOnyx for Skincare Applications

NEW YORK (GenomeWeb News) – DNA Electronics today announced a deal making its nucleic acid testing platform available to geneOnyx for cosmetic and skincare applications.

The commercial license and supply agreement provides geneOnyx access to DNA Electronics' Genalysis platform, which geneOnyx will use to analyze a person's genetic makeup to determine how that person will react to certain product ingredients.

Financial and other terms of the deal were not disclosed.

DNA Electronics said that the deal brings it into the non-in vitro diagnostic space. Pilot trials focused on the clinical diagnostics space for Genalysis are set to begin later this year.

Genalysis is a real-time, nucleic acid testing platform that delivers point-of-need results in about 30 minutes, using a sample processing kit and interchangeable test cartridges plugged into a USB stick or other electronic reader. Using a saliva sample from a mouth swab, purified, amplification-ready DNA is delivered to a complementary metal oxide semiconductor-based test cartridge, which amplifies and detects genetic signatures in the DNA.

Based in London, DNA Electronics develops electronic microchip-based tests for real-time nucleic acid detection. It has worldwide non-exclusive licensing deals with Roche's 454 Life Sciences and Life Technologies' Ion Torrent providing those firms access to parts of its technology for use in semiconductor sequencing.

geneOnyx provides cloud-based genetic analytics services and technology for cosmetic applications.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more